首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1547891

全球呼吸道疾病疫苗市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测

Global Respiratory Disease Vaccine Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球呼吸系统疾病疫苗市场需求预计将从2023年的946.5亿美元达到近1,133.2亿美元的市场规模，2024-2032年研究期间复合年增长率为2.02%。

呼吸系统疾病是指攻击呼吸系统（包括肺部和其他部位）的疾病。呼吸道疾病最常见的原因是细菌和病毒感染。其他原因包括空气污染和吸烟。呼吸道疾病包括肺炎（细菌性、病毒性）、流感、慢性阻塞性肺病（COPD）、气喘、肺癌和肺纤维化。疫苗接种被认为是对抗传染病最安全的方法。单一疫苗或疫苗组合应该对此类疾病有效。

市场动态

全球市场的主要动力包括呼吸系统疾病盛行率的上升和慢性阻塞性肺病的增加。政府组织正在支持疫苗生产，以此作为预防呼吸道疾病的一步。大量呼吸道疾病疫苗正在研发中，并在全世界进行临床试验。主要市场参与者正在投资研发以开发功效增强的疫苗。所有因素加在一起预计将提振市场。 COVID-19 大流行是由 SARS-COV-2 病毒引起的呼吸道疾病。目前，世界上还没有可以治癒该疾病的抗病毒药物或疫苗。全球许多製药组织正在努力儘早开发疫苗。由于需求庞大，预计此次大流行将快速推动全球呼吸道疾病市场的发展。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球呼吸道疾病疫苗市场的各个细分市场进行了包容性评估。呼吸道疾病疫苗产业的成长和趋势为本研究提供了整体方法。

市场区隔

呼吸道疾病疫苗市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按类型

病毒疫苗
细菌疫苗
联合疫苗

按年龄段

儿科
成人

透过感染

新冠肺炎
流感
呼吸道合胞病毒 (RSV)
肺炎
其他的

按配销通路

医院和零售药房
政府供应商
其他的

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲呼吸道疾病疫苗市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。呼吸道疾病疫苗市场的主要参与者包括葛兰素史克公司、强生服务公司、辉瑞公司、赛诺菲、印度血清研究所。 Ltd.、Sinovac、Bavarian Nordic、Merck & Co. Inc.、AstraZeneca、Emergent、Novavax、INOVIO Pharmaceuticals、Moderna Inc.。合作伙伴关係、财务概览、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

简介 - 市场动态
市场驱动因素
市场限制
机会
产业动态
波特五力分析
市场吸引力分析
- 按类型分類的市场吸引力分析
- 按年龄组别分類的市场吸引力分析
- 按感染情况进行的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区

第 4 章：价值链分析

价值链分析
原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
潜在买家名单
行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势

第 5 章：全球呼吸系统疾病疫苗市场分析：按类型

按类型概述
历史和预测数据
按类型分析
病毒疫苗
细菌疫苗
联合疫苗

第 6 章：全球呼吸系统疾病疫苗市场分析：按年龄组别划分

按年龄组别概述
历史和预测数据
按年龄组分析
儿科
成人

第 7 章：全球呼吸道疾病疫苗市场分析：依感染状况

按感染概述
历史和预测数据
按感染情况分析
新冠肺炎
流感
呼吸道合胞病毒 (RSV)
肺炎
其他的

第 8 章：全球呼吸道疾病疫苗市场分析：按分销管道

配销通路概述
历史和预测数据
按配销通路分析
医院和零售药房
政府供应商
其他的

第 9 章：全球呼吸道疾病疫苗市场分析：依地理位置

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区按国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲按国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 10 章：呼吸道疾病疫苗公司的竞争格局

呼吸系统疾病疫苗市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 11 章：公司简介

顶级公司市占率分析
市场集中度
GSK Plc.

公司概况
公司收入
产品
最新动态

Johnson & Johnson Services Inc.

公司概况
公司收入
产品
最新动态

Pfizer Inc.

公司概况
公司收入
产品
最新动态

Sanofi

公司概况
公司收入
产品
最新动态

Serum Institute Of India Pvt. Ltd.

公司概况
公司收入
产品
最新动态

Sinovac

公司概况
公司收入
产品
最新动态

Bavarian Nordic

公司概况
公司收入
产品
最新动态

Merck & Co. Inc.

公司概况
公司收入
产品
最新动态

AstraZeneca

公司概况
公司收入
产品
最新动态

Emergent

公司概况
公司收入
产品
最新动态

Novavax

公司概况
公司收入
产品
最新动态

INOVIO Pharmaceuticals

公司概况
公司收入
产品
最新动态

Moderna Inc

公司概况
公司收入
产品
最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

简介目录图表

Product Code: VMR11212585

The global demand for Respiratory Disease Vaccine Market is presumed to reach the market size of nearly USD 113.32 Billion by 2032 from USD 94.65 Billion in 2023 with a CAGR of 2.02% under the study period 2024-2032.

Respiratory diseases are the diseases that attack the respiratory system, including lungs and the other parts. The most common causes of respiratory diseases are bacterial and viral infections. Other reasons include air pollution and smoking. Respiratory diseases include pneumonia (bacterial, viral), influenza, chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and pulmonary fibrosis. Vaccination is considered to be the safest way to fight infectious diseases. A single vaccine or combination of vaccines is supposed to be effective against such diseases.

MARKET DYNAMICS

The prime movers of the global market include the rising prevalence of respiratory disorders, increasing chronic obstructive pulmonary disease. Government organizations are supporting vaccine production as a step forward to prevent respiratory diseases. A large number of respiratory disease vaccines are in the pipeline, and undergoing clinical trials in the entire world. The key market players are investing in R & D to develop vaccines with enhanced efficacy. All the factors altogether are expected to boost the market. COVID-19 pandemic is a respiratory disease caused SARS-COV-2 virus. Currently, there is no antiviral drug or vaccine available in the world to cure the disease. A large number of pharmaceutical organizations across the globe are working strenuously to develop the vaccine at the earliest. The pandemic is expected to drive the global respiratory disease market at a fast pace owing to massive demand.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Respiratory Disease Vaccine. The growth and trends of Respiratory Disease Vaccine industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Respiratory Disease Vaccine market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Viral Vaccine
Bacterial Vaccine
Combination Vaccine

By Age Group

Pediatric
Adult

By Infection

COVID-19
Influenza
Respiratory Syncytial Virus (RSV)
Pneumonia
Others

By Distribution Channel

Hospital & Retail Pharmacies
Government Suppliers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Respiratory Disease Vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Respiratory Disease Vaccine market include GSK Plc., Johnson & Johnson Services Inc., Pfizer Inc., Sanofi, Serum Institute Of India Pvt. Ltd., Sinovac, Bavarian Nordic, Merck & Co. Inc., AstraZeneca, Emergent, Novavax, INOVIO Pharmaceuticals, Moderna Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RESPIRATORY DISEASE VACCINE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Age Group
- 3.7.3 Market Attractiveness Analysis By Infection
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Viral Vaccine Historic and Forecast Sales By Regions
5.5. Bacterial Vaccine Historic and Forecast Sales By Regions
5.6. Combination Vaccine Historic and Forecast Sales By Regions

6. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY AGE GROUP

6.1. Overview By Age Group
6.2. Historical and Forecast Data
6.3. Analysis By Age Group
6.4. Pediatric Historic and Forecast Sales By Regions
6.5. Adult Historic and Forecast Sales By Regions

7. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY INFECTION

7.1. Overview By Infection
7.2. Historical and Forecast Data
7.3. Analysis By Infection
7.4. COVID-19 Historic and Forecast Sales By Regions
7.5. Influenza Historic and Forecast Sales By Regions
7.6. Respiratory Syncytial Virus (RSV) Historic and Forecast Sales By Regions
7.7. Pneumonia Historic and Forecast Sales By Regions
7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital & Retail Pharmacies Historic and Forecast Sales By Regions
8.5. Government Suppliers Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL RESPIRATORY DISEASE VACCINE MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RESPIRATORY DISEASE VACCINE COMPANIES

10.1. Respiratory Disease Vaccine Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF RESPIRATORY DISEASE VACCINE INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. GSK Plc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Johnson & Johnson Services Inc.
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Pfizer Inc.
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Sanofi
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Serum Institute Of India Pvt. Ltd.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Sinovac
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Bavarian Nordic
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Merck & Co. Inc.
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. AstraZeneca
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Emergent
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Novavax
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments
11.14. INOVIO Pharmaceuticals
- 11.14.1 Company Overview
- 11.14.2 Company Revenue
- 11.14.3 Products
- 11.14.4 Recent Developments
11.15. Moderna Inc
- 11.15.1 Company Overview
- 11.15.2 Company Revenue
- 11.15.3 Products
- 11.15.4 Recent Developments